Published in Vaccine Weekly, July 31st, 2002
"These study results further demonstrate the potential of our proprietary CAP technology to allow oral or intranasal formulations of vaccines that previously had to be administered by injection," said Stephen M. Simes, president and chief executive officer of BioSante. "This is not only more convenient and less painful than...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.